MB-103

N/A

Report date: 2024/04/16 14:31:46

Base Information

Drug NameMB-103
Drug Alias NameHER2-specific chimeric antigen receptor T cells (Mustang Bio)MB 103 HER2-specific CAR T cells (Mustang Bio)HER2-targeted CAR T cell therapy (Mustang Bio)MB-103HER2(EQ)BBζ/CD19t+ Tcm +[7] 
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-HER2
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBrain metastasesMeningeal NeoplasmsBreast Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCity Of Hope National Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesMustang Bio IncCity Of Hope National Medical Center
Inactive CompaniesN/A
Active IndicationsBrain metastasesMeningeal NeoplasmsBreast Neoplasms +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A